This was accompanied by a positive correlation between EZH2 downregulation and LINE-1 methylation levels, as well as an inverse correlation between DNMT3B expression and global LINE-1 methylation levels, suggesting that these treatments may restore epigenetic balance by repressing oncogenic pathways (via EZH2) and reducing DNMT3B-associated demethylation, thereby contributing to genome stabilization in K1 human thyroid cancer cells. This evidence concerns the gene EZH2 and thyroid cancer.